“This tender is one of the first we have seen in Italy with a specific focus on rapid AST solutions directly from positive blood culture bottles and we are excited to participate with ASTar Instrument and Consumables. We know there are preparations for tenders at other sites and are very optimistic about the competitiveness of ASTar,” said Thomas Fritz, Chief Commercial Officer at Q-linea. 

“It is encouraging to see tender activity picking up in one of the major diagnostic markets in Europe. To us, it is proof that the decision to build our own legal presence in Italy was correct. We do not plan to communicate our participation in every tender in the future, but since this is the first we respond to as Q-linea, we would like to share this news,” said Jonas Jarvius, CEO and President at Q-linea.  

About ASTar Instruments and ASTar BC G-Kit 
ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.  

ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.